老年慢性心力衰竭患者NT—proBNP检测及其临床意义

【目的】探讨检测N端脑利钠肽前体（NT-proBNP）水平在老年慢性心力衰竭患者的临床应用价值。【方法】采用电化学发光法测定80例治疗前后老年慢性心力衰竭患者（心衰组）和60例健康对照者血清（对照组）NT-proBNP水平，心力衰竭患者心功能按NYHA心功能分级，以6分钟步行试验评价运动耐量。【结果】心衰组NT-proBNP水平较对照组明显升高E（5052．6土1860．4）pg／mLvs（220．4士99．2），pg／mL，P〈0．O11；心衰组治疗后NT-proBNP水平较治疗前明显降低[（5052．6±4-1860．4）pg／mLVS（3203±1453．4）pg／mL，Pd0．01）]。NT-proBNP水平与左室射血分数（LVEF）（r=-O．174，Pd0．05）和6分钟步行距离成显著负相关（r=-0．187，Pd0．05）。【结论】老年慢性心力衰竭患者NT—proBNP水平明显增高，其检测水平可反映老年心力衰竭患者心功能状态、运动耐量，并可作为疗效判断指标。

Detection of NT-proBNP in Elderly Patients with Chronic Heart Failure and Its Significance

[Objective]To explore the clinical value of N-terminal pro-B type natriuretic peptide （NT-proBNP） level in elderly patients with chronic heart failure. [Methods]Electrochemiluminescence assay was used to measure the serum level of NT-proBNP in 80 elderly patients with chronic heart failure（heart failure group） and 60 healthy controls（control group）. According to NYHA grading, the cardiac function of heart failure patients was graded. Six-minute walking test was used to evaluate the exercise tolerance.[Results] Compared with control group, serum NT-proBNP level in heart failure group increased significantly[-（5052.6 ~ 1860.4） pg/mL vs （220.4±99.2） pg/mL3（ P 〈0.01）. After therapy, serum NT-proBNP level in heart failure group was significantly lower than that before therapy（5052.6 ±1860.4 vs 3203± 1453.4, P 〈0.01）. Serum NT- proBNP level was negatively correlated with left ventricular ejection fraction（r= -0. 174, P d0.05） and 6-minute walking distance（r=-0. 187, P 〈0.05）. [Conclusion] Serum NT-proBNP level in elderly patients with chronic heart failure increases significantly. Measuring the NT-proBNP level can evaluate the heart function and exercise tolerance and be used as the indicator of the therapeutic efficacy.